Australia's most trusted
source of pharma news
Thursday, 07 November 2024
Posted 4 November 2024 AM
Lupin has its eye on Otsuka's kidney disease treatment Jinarc and Besin Healthcare's contraceptive Slinda, registering the first generic versions of both drugs last week.
Jinarc became the first medicine TGA approved to treat autosomal dominant polycystic kidney disease in 2017 and its PBS listing in 2019 was hailed a "key achievement" for the Japanese pharma as it celebrated 10 years of operations in Australia last month.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.